

Helen L Reeves

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7352965/publications.pdf>

Version: 2024-02-01

79
papers

7,910
citations

117625

34
h-index

69250

77
g-index

83
all docs

83
docs citations

83
times ranked

9475
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade. <i>Journal of Clinical Oncology</i> , 2015, 33, 550-558.	1.6	1,810
2	From NASH to HCC: current concepts and future challenges. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 411-428.	17.8	872
3	Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team. <i>Journal of Hepatology</i> , 2014, 60, 110-117.	3.7	487
4	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014, 5, 4309.	12.8	478
5	KLF6, a Candidate Tumor Suppressor Gene Mutated in Prostate Cancer. <i>Science</i> , 2001, 294, 2563-2566.	12.6	408
6	The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 144-153.	2.5	217
7	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 875-886.e6.	4.4	217
8	A Germline DNA Polymorphism Enhances Alternative Splicing of the KLF6 Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk. <i>Cancer Research</i> , 2005, 65, 1213-1222.	0.9	202
9	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. <i>Scientific Reports</i> , 2017, 7, 4492.	3.3	193
10	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021, 74, 775-782.	3.7	193
11	Cyclin-Dependent Kinase Inhibition by the KLF6 Tumor Suppressor Protein through Interaction with Cyclin D1. <i>Cancer Research</i> , 2004, 64, 3885-3891.	0.9	152
12	Targeted Inhibition of the KLF6 Splice Variant, KLF6 SV1, Suppresses Prostate Cancer Cell Growth and Spread. <i>Cancer Research</i> , 2005, 65, 5761-5768.	0.9	151
13	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. <i>British Journal of Cancer</i> , 2016, 114, 744-750.	6.4	150
14	Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. <i>Hepatology</i> , 2004, 40, 1047-1052.	7.3	142
15	Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. <i>Journal of Hepatology</i> , 1996, 25, 677-683.	3.7	139
16	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. <i>Nature Cancer</i> , 2022, 3, 386-401.	18.2	126
17	Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1234-1245.	2.3	111
18	Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2021, 75, 865-878.	3.7	111

#	ARTICLE	IF	CITATIONS
19	Neutrophils induce paracrine telomere dysfunction and senescence in ROS-dependent manner. <i>EMBO Journal</i> , 2021, 40, e106048.	7.8	101
20	Imagestream detection and characterisation of circulating tumour cells – A liquid biopsy for hepatocellular carcinoma?. <i>Journal of Hepatology</i> , 2016, 65, 305-313.	3.7	98
21	Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis. <i>Journal of Hepatology</i> , 2015, 62, 1296-1303.	3.7	92
22	Liquid biopsy for liver diseases. <i>Gut</i> , 2018, 67, 2204-2212.	12.1	79
23	Neutrophils as potential therapeutic targets in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 257-273.	17.8	77
24	Stress-activated protein kinases in the activation of rat hepatic stellate cells in culture. <i>Journal of Hepatology</i> , 2000, 32, 465-472.	3.7	74
25	DNA-PK – A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival. <i>Clinical Cancer Research</i> , 2015, 21, 925-933.	7.0	74
26	Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?. <i>British Journal of Cancer</i> , 2018, 118, 248-257.	6.4	71
27	The CCR2+ Macrophage Subset Promotes Pathogenic Angiogenesis for Tumor Vascularization in Fibrotic Livers. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 7, 371-390.	4.5	71
28	CXCR2 inhibition enables NASH-HCC immunotherapy. <i>Gut</i> , 2022, 71, 2093-2106.	12.1	66
29	In Vitro Cytotoxicity of 150 Chemicals to 3T3-L1 Cells, Assessed by the FRAME Kenacid Blue Method. <i>ATLA Alternatives To Laboratory Animals</i> , 1988, 16, 84-95.	1.0	63
30	Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012, 55, 1083-1093.	7.3	55
31	Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. <i>Journal of Hepatology</i> , 2013, 58, 1000-1006.	3.7	50
32	High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. <i>International Journal of Cancer</i> , 2016, 138, 206-216.	5.1	45
33	Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy. <i>Journal of Clinical Investigation</i> , 2019, 130, 258-271.	8.2	45
34	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017, 6, 1930-1940.	2.8	43
35	Cell-free DNA TAPS provides multimodal information for early cancer detection. <i>Science Advances</i> , 2021, 7, eabh0534.	10.3	41
36	Rare ATG7 genetic variants predispose patients to severe fatty liver disease. <i>Journal of Hepatology</i> , 2022, 77, 596-606.	3.7	38

#	ARTICLE	IF	CITATIONS
37	Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, 2021, 3, 100260.	4.9	36
38	Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 2018, 73, 369-385.	2.9	35
39	Hepatocellular carcinoma in non-alcoholic fatty liver disease—a review of an emerging challenge facing clinicians. Hepatobiliary Surgery and Nutrition, 2021, 10, 59-75.	1.5	34
40	NAFLD-Associated HCC: Progress and Opportunities. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 223-239.	3.7	33
41	Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 167-181.	7.7	28
42	The role of phosphatidic acid in platelet-derived growth factor-induced proliferation of rat hepatic stellate cells. Hepatology, 2000, 31, 95-100.	7.3	26
43	Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM - Monthly Journal of the Association of Physicians, 2016, 110, hcw151.	0.5	26
44	A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC?. Cancers, 2021, 13, 1412.	3.7	26
45	Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes. Diabetes, Obesity and Metabolism, 2017, 19, 1078-1087.	4.4	21
46	AISF position paper on liver transplantation and pregnancy. Digestive and Liver Disease, 2016, 48, 860-868.	0.9	20
47	Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance. Journal of Hepatology, 2015, 62, 982-983.	3.7	19
48	High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma. Liver International, 2021, 41, 828-836.	3.9	19
49	COVID-19 and liver cancer: lost patients and larger tumours. BMJ Open Gastroenterology, 2022, 9, e000794.	2.7	19
50	Assessment of the Hong Kong Liver Cancer Staging System in Europe. Liver International, 2016, 36, 911-917.	3.9	16
51	Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. Journal of Hepatocellular Carcinoma, 2019, Volume 6, 23-30.	3.7	16
52	Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy. Cell Death and Disease, 2022, 13, 143.	6.3	16
53	Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy. Journal of Clinical and Experimental Hepatology, 2016, 6, 186-194.	0.9	13
54	Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer, 2016, 115, 797-804.	6.4	13

#	ARTICLE	IF	CITATIONS
55	Regioselective sulfamoylation at low temperature enables concise syntheses of putative small molecule inhibitors of sulfatases. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 5279-5284.	2.8	12
56	Early Experience of Trans-arterial Chemo-Embolisation for Hepatocellular Carcinoma with a Novel Radiopaque Bead. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1563-1570.	2.0	12
57	Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 17-29.	0.9	12
58	Key features of the environment promoting liver cancer in the absence of cirrhosis. <i>Scientific Reports</i> , 2021, 11, 16727.	3.3	12
59	Reply:. <i>Hepatology</i> , 2005, 41, 682-683.	7.3	11
60	Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	3.9	11
61	<p>Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population</p>. <i>Hepatic Medicine: Evidence and Research</i> , 2019, Volume 11, 47-67.	2.5	10
62	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. <i>Cell Death and Disease</i> , 2021, 12, 555.	6.3	10
63	Treatment strategies for early stage hepatocellular carcinoma: a systematic review and network meta-analysis of randomised clinical trials. <i>Hpb</i> , 2021, 23, 495-505.	0.3	9
64	HCV Activates Somatic L1 Retrotranspositionâ€™A Potential Hepatocarcinogenesis Pathway. <i>Cancers</i> , 2021, 13, 5079.	3.7	7
65	Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?. <i>Liver Cancer</i> , 2022, 11, 540-557.	7.7	6
66	Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases. <i>Chemical Science</i> , 2016, 7, 2821-2826.	7.4	5
67	Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease. <i>Liver Cancer</i> , 2023, 12, 19-31.	7.7	5
68	NAFLDâ€™which patients should have hepatocellular carcinoma surveillance?. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 353-355.	1.5	4
69	A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification. <i>Journal of Hepatology</i> , 2020, 73, S13-S14.	3.7	4
70	A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma. <i>Journal of Visualized Experiments</i> , 2021, , .	0.3	3
71	Combined hepatocellularâ€™cholangiocarcinoma â€™ More questions than answers. <i>Liver International</i> , 2021, 41, 1186-1188.	3.9	2
72	Mapping of population disparities in the cholangiocarcinoma urinary metabolome. <i>Scientific Reports</i> , 2021, 11, 21286.	3.3	2

#	ARTICLE	IF	CITATIONS
73	The feasibility and acceptability of a home-based, virtual exercise intervention for older patients with hepatocellular carcinoma: protocol for a non-randomised feasibility study (TELEX-Liver Cancer). Pilot and Feasibility Studies, 2022, 8, .	1.2	2
74	Reply to "Hepatocellular carcinoma and the Newcastle-upon-Tyne area". Journal of Hepatology, 2014, 60, 1330-1331.	3.7	1
75	Signed, SEALED, detected I TM your patient with advanced fibrosis or cirrhosis!. Journal of Hepatology, 2022, , .	3.7	1
76	Selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC): informing clinical practice for multidisciplinary teams in England. Frontline Gastroenterology, 2023, 14, 45-51.	1.8	1
77	Reply to "Comment on "Circulating Neutrophils in patients with hepatocellular carcinoma". British Journal of Cancer, 2018, 119, 781-782.	6.4	0
78	High subcutaneous tissue density correlates negatively with survival in patients with hepatocellular carcinoma. Journal of Hepatology, 2020, 73, S383-S384.	3.7	0
79	Rare <i>Atg7</i> Genetic Variants Predispose to Severe Fatty Liver Disease. SSRN Electronic Journal, 0, , .	0.4	0